Equine vets and farriers in South Wales who need horses x-rayed can now use a new mobile service offered by Equiray. Operating 24 hours a day, 7 days a week, Equiray's technicians travel to the site to take digital x-rays, using state-of-the-art imaging equipment.
At the heart of Equiray's service is the Uno Equine portable digital x-ray system; the only system in the world that has a capture screen built into the generator. All images taken can be viewed within minutes and decisions made there and then regarding further tests. The x-ray images are emailed to the veterinary surgeon immediately, or supplied to the practice on a CD or memory stick. They are also stored securely by Equiray for a 3 month period.
For farriers, the image can be displayed on screen so they can see the internal bone structures encapsulated within the hoof before they start remedial work, and then another x-ray taken after the work has been completed. Both images can be viewed together for comparison.
Equiray says its service means practices don't have to buy and maintain costly equipment, nor send a practice technician to attend with the vet, as all Equiray technicians are highly skilled in equine imaging.
Equiray currently operates mainly in South Wales but with requests coming from other areas of the country, the company says its technicians are travelling to x-ray several horses in a particular area, over a 2 day period. Remedial farriers requiring monthly x-rays of certain horses are also using the service and plans to extend the service nationally are in progress.
For more information, visit www.equiray.co.uk/
Vets attending the first veterinary-led European Equine Transport Forum, held in Brussels last November, have agreed that the profession needs to take a leading role to help enforce the current regulation governing the long-distance transport of horses, in order for equine welfare standards to be improved.
In support, the British Equine Veterinary Association (BEVA) Trust has announced the introduction of the BEVA Trust Equine Transport Enforcement Award of €1000, to be given annually to the individual or group doing the most to improve enforcement of the current transport regulation.
The Forum was initiated by BEVA President Madeleine Campbell in conjunction with the Federation of Veterinarians of Europe (FVE) and is sponsored by the BEVA Trust and World Horse Welfare. It attracted representatives from 38 nations; including a strong turnout from Eastern Europe where horses sourced for slaughter often start their journeys and Italy which is the end destination for the majority of these horses.
The plight of horses sourced for slaughter was the main focus for discussion and the key issues raised were:
Delegates also examined the long-term need to change the attitude of Italian consumers, raising awareness of the current welfare issues related to their preference for fresh meat, labelled as Italian produce. In addition they discussed the impact on equine welfare of increased profits in sourcing horses in Eastern Europe and then transporting them long distances for slaughter.
Dr Madeleine Campbell said: "The atmosphere throughout the day was one of collaboration and determination to succeed. Proper enforcement of the current regulation is the key to welfare improvements, as is the need for a system of best practice to drive a change in cultural attitudes about how horse meat is produced. A process of education is necessary so that consumers understand the welfare issues associated with long-distance transport and start demanding accurate information about where the meat which they are buying originally came from, and how far the horses travelled to slaughter. We are all in agreement that vets have a pivotal role to play in both education and enforcement, and that they want to play it."
Nominations for the annual BEVA Trust Equine Transport Enforcement Award are open and can be made via the FVE and the BEVA Trust. The award will be judged by the FVE Working Group on Transport, and will be awarded for the first time in November 2011. The programme, abstracts and presentations from the Forum can be found at: http://www.fve.org/events/index.html#conferences
Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.
According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative joint disease, also known as non-infectious arthritis or osteoarthritis. The product is licensed in the UK for the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis. This is a critical treatment area since equine degenerative joint disease is estimated to cause up to one-third of all equine lameness cases1. It most commonly affects the hocks and coffin joints with the most severe effects on the high-motion knee and fetlock joints.
Esther Rawlinson MRCVS, Global Technical Services Manager for the Novartis Animal Health Companion Animal Business in the Therapeutics & Equine areas said: "Adequan Equine is a leading joint treatment for horses and is widely used by veterinarians in the equine sport industry. Adequan Equine reduces pain and lameness in horses while at the same time stimulating cartilage repair.
Adequan Equine 100mg/ml solution contains polysulphated glycosaminoglycan for intramuscular injection. It is a chondroprotective, meaning it inhibits the breakdown of cartilage in diseased joints while at the same time supporting its repair.
Adequan Equine works by blocking the destructive enzymes formed in the joint as a result of inflammation while stimulating the production of hyaluronic acid to restore the synovial fluid, and the synthesis of cartilage building compounds.
Dechra Pharmaceuticals PLC has announced that it has acquired the entire issued share capital of Genitrix Limited ("Genitrix") from its owner managers for an initial cash consideration of £5.4 million, with a further £0.8 million being payable upon achievement of specific milestones.
Dechra says the acquisition of Genitrix is consistent with its strategy to grow its international veterinary pharmaceutical business. In the year ended 31 March 2010, Genitrix achieved revenues of £2.4 million.
Ian Page, Chief Executive of Dechra, said: "Genitrix range of equine and companion animal products enhances and complements our UK product portfolio. Furthermore the recently approved canine epilepsy product, Libromide, provides future growth opportunities through potential mutual recognition in Europe. The acquisition is expected to be earnings enhancing in the first full year following ownership."
Pfizer Animal Health is advising vets and horse owners to be on guard against the threat of West Nile Virus (WNV) in the UK, following a spate of outbreaks of the disease in several European countries this year.
West Nile Virus has recently made headline news because of a human outbreak in Greece which resulted in a number of deaths. Outbreaks have also occurred in Russia, Romania and Italy during 2010. West Nile Fever is a viral disease transmitted by mosquitoes, which carry the virus after biting infected birds. Primarily occurring between July and October, in line with typical peak activity of mosquitoes, it can have serious consequences on human and equine health, with severe cases resulting in fatal neurological disease.
There is no cure, though supportive treatment can aid recovery. However if the disease progresses to a state where the animal is not able to stand up, their chance of survival is considered low. Prevention of infection is difficult, but any steps that reduce mosquito numbers or the likelihood of horses and people being bitten may help to reduce the risk in areas where the disease is present. However, the only way to reduce the risk of an individual horse developing disease due to WNV is through vaccination.
Ben Gaskell, Pfizer's equine veterinary advisor said: "West Nile Virus may well become a very real threat to both horses and humans in Northern Europe. It is important for vets, horse owners and infectious disease experts to work together to mitigate its impact in the event of the virus becoming endemic across Europe. The rapid spread of the disease across North America is an illustration of what could potentially happen in Europe and it is important to remember there is no curative treatment - the only way to prevent clinical disease in horses is by vaccination."
Pfizer Animal Health supports the PrEquID (Prevention of Equine Infectious Disease) group, which consists of internationally recognised equine and infectious disease experts. The group was formed to develop guidelines on the prevention and control of a number of equine infectious diseases, on a global basis.
Klaus Osterrieder, Professor and Chair in the Institut für Virologie in the Veterinärfakultät at Freie Universität Berlin, Germany and a member of the PrEquID group advises: "Horse owners should ask their veterinarian for advice on appropriate prevention measures. Experience has shown that adopting a prudent prevention strategy can be a very effective way of managing this devastating disease."
Further information on WNV is available at www.westnile.eu.
To mark today's European Antibiotic Awareness Day 2010, the British Veterinary Association is warning veterinary surgeons in the UK that failure to use antimicrobials responsibly could result in their use being restricted.
The BVA promotes the responsible use of antimicrobials and last year published a poster and guidance for vets: 'Responsible use of antimicrobials in veterinary practice: the 8-point plan'. According to the association, the poster received very positive feedback from across the UK and from the Federation of Veterinarians of Europe (FVE).
Concerns regarding resistance to antimicrobials and antibiotics span both the human and animal medicine fields and in 2008 the Chief Medical Officer called for a ban on the use of certain types of antibiotics in animals in order to protect their activity in humans.
Furthermore some EU Member States already restrict the availability of antimicrobials to veterinary surgeons and adopt a strict formulary approach to the medicines that they can prescribe. The BVA says it is concerned that this trend will reach the UK and the freedom of vets to prescribe according to their clinical judgement will be restricted.
Harvey Locke, President of the BVA, said: "Antimicrobial resistance is an enormous problem for both human and animal health. As veterinary surgeons we have a duty to use these medicines responsibly for the good of animal health and welfare as well as public health.
"The BVA's poster on responsible use should be displayed in veterinary practices across the UK as a constant reminder, and I would urge all vets to refer to it.
"Failure to heed the message of responsible use could result in vets losing the right to prescribe certain medicines, which could have a significant impact on animal health and welfare.
"On Antibiotic Awareness Day our message to vets is clear: use them responsibly or lose them."
Ceva Animal Health has produced a new booklet explaining the discharge procedures for horses that have been treated with Equidronate (formerly called Tildren), a bisphosphonate infusion used for the treatment of bone spavin.
Ceva says the new booklet is designed for vets to give their clients to help convey the most effective post-treatment management protocol. It explains what Equidronate is, how it works and how it is administered. It goes on to cover how owners can help to monitor progress once exercise has commenced, by completing the specially created assessment forms contained within the booklet every couple of weeks.
According to the company, trials published earlier this year show that horses suffering lameness caused by bone spavin can show marked improvement following treatment with an Equidronate infusion, in combination with controlled exercise.
Copies of the new leaflet are available free of charge from your Ceva sales representative. Leaflets on understanding bone spavin, understanding navicular disease and understanding sacroiliac disease are also available.
Horiba Medical - UK has launched MLT-Diode Laser Systems, specifically designed for veterinary use, as part of its portfolio of animal healthcare products.
According to the company, the MLT-Diode Lasers are highly versatile and can be used in a variety of veterinary applications including surgery, endoscopy, dentistry and irradiation.
The two models, the MLT-Diode Laser Classic and Premium, both feature touch screen controls and are adaptable to each users individual preferences. Designed with small animal practices in mind, the Classic has a performance out-put of 8 watts whilst the more powerful Premium model is for equine medicine with an output of 15 watts. The system is mounted on a mobile cart with a protection case, allowing the whole system to be moved between treatment rooms and enabling near patient application.
Horiba Medical will be exhibiting the MLT-Diode Laser Systems at the London Vet Show at Olympia, 22nd to 23rd October 2010, on Stand M4.
Boehringer Ingelheim Vetmedica has launched Prascend, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushing's Disease.
Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets.
Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica said: "Many horses and ponies with Cushing's Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future.
"We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market."
For further information, visit www.prascend.co.uk or call 01344 746959
Elanco, a division of Eli Lilly and Company, has launched into the UK companion animal market with a pledge to listen to vets and provide a highly personalised level of support.
The company will initially offer recognised brands such as equine vaccines from the Duvaxyn range, Felocell vaccine for cats and equine wormer Strongid P. It says it is also developing a range of innovative new products designed to address the unmet needs of companion animals, the first of which are expected to be launched during 2011.
Mrs Tina Hunt, a Glasgow Vet School graduate and most recently, Veterinary Business Director at Fort Dodge UK, has been appointed with a remit to build the Elanco Companion Animal Health organisation in the UK. Reporting to Jannes Nijland, Director Elanco Western Europe, she will spearhead the company's growth and relationship building with veterinary practices across the country.
Tina said: "Recent changes in the animal health sector make it an exciting time to be launching a new companion animal brand. The opportunity to be in at the start and to shape a completely new business from scratch was too good to miss. My team shares a passion to combine the best of our experience with new approaches and new ways of working which are more closely attuned to what vets actually want. This means doing things differently and this is a challenge we relish.
We seek a genuine partnership with the profession and look forward to building close, individual relationships with vets and practices, helping them to enable companion animals to live longer, healthier and higher quality lives. While we're a newcomer in this sector, we benefit from the track record and resources available to Elanco, the fifth largest animal company in the world. We're determined to make Elanco Companion Animal Health a trusted and valued partner to vets working in companion animal practice."
Elanco develops and markets products to improve animal health and food-animal production in more than 75 countries. The company employs more than 2,300 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a pharmaceutical corporation. Additional information about Elanco is available at www.elancopet.com and the company can be contacted via email: elancoCAH.uk@lilly.com
A research project funded by The Horse Trust has discovered that a racehorse's performance does not markedly change after it has recovered from a tendon injury.
The research was led by Bryan O'Meara, who is in the final year of a three year clinical training scholarship funded by The Horse Trust.
Mr. O'Meara carried out the research at Donnington Grove Veterinary Surgery in Newbury, under the supervision of epidemiologist Dr Tim Parkin from University of Glasgow.
Tendonitis is one of the most common musculoskeletal injuries in racehorses, with a prevalence of 11-30%, according to earlier research.
Mr. O'Meara examined the clinical records and racing histories of 400 racehorses who had been treated for superficial digital flexor (SDF) tendonitis injuries over a five year period (2003-2008).
The race records of horses affected by tendon injury were compared with 400 matched control horses that had never suffered SDF tendon injuries.
The controls were horses training in the same establishment at the time of injury and of the same age and sex as the case horse.
The research looked at the performance of the racehorses in races before and after treatment for the injury, and at the performance of the control horses before and after the treatment date. The Racing Post Rating (RPR), which is published by the Racing Post after every race, was used as a measure of performance.
Mr. O'Meara found that there was no significant difference in RPR before and after the treatment date in case and control horses.
According to The Horse Trust, this result is unexpected as in vitro studies have found that healed tendon tissue has reduced elasticity due to the presence of scar tissue. This suggests that a horse with a healed SDF tendon would need to work its muscles harder to compensate and would therefore be expected to have lower performance.
Mr. O'Meara said more research is needed to back-up his finding that performance isn't significantly affected by tendon injury: "It could be that using Racing Post Rating to measure performance isn't sensitive enough to pick up a change in the horse's performance. However, it's encouraging that there's no marked change in performance after a horse has recovered from a tendon injury. These findings show that there's no need to give up on a horse that has a tendon injury - they can still come back and perform well, or can be used for other, less demanding riding activities."
The research also found that there was no significant difference between case and control horses when returning to racing and completing three races. Only after completing five races, or three years post treatment, was a significant difference found between case and control horses. This finding is a step towards developing a more accurate assessment of tendon treatment. Outcome after five races or three years post treatment is a better indicator of the outcome of treatment.
Mr. O'Meara said: "At the moment, some tendon treatments state their success as the percentage of horses that return to racing after treatment. However, we've shown that there's no significant difference between case and control horses at this time. At the moment, there are a myriad of treatments available to treat tendonitis. Hopefully this finding will be used in further research to learn which treatments are most effective."
Mr O'Meara's research also found a link between SDF tendon injury and the racehorse competing at its maximum performance level: the case horses were significantly nearer to their pre-injury maximum performance level in the race immediately before injury (compared to matched controls), suggesting that they were competing nearer their individual maximum performance level when the SDF tendon injury occured.
Dechra Veterinary Products has launched Ketodale, an anti-inflammatory injection for cattle, horses and swine.
Ketodale contains the non-steroidal anti-inflammatory drug ketoprofen 100mg/ml. It is indicated for use in cattle and swine for diseases associated with inflammation, pain or fever. In cattle these include respiratory diseases, mastitis, osteoarticular and muscular-skeletal disorders, such as lameness and arthritis, and to ease pain post parturition. Ketodale can be used to treat swine suffering from Mastitis Metritis Agalactia (MMA) Syndrome and respiratory tract infections.
In horses, Ketodale is indicated for diseases affecting the osteoarticular and muscular-skeletal system associated with pain and inflammation. These include naviculitis, arthritis and laminitis. It can also be used for post-surgical inflammation and symptomatic therapy of colic and fever.
Ketodale is available in 50ml and 100ml vials.
To coincide with the product's launch, Dechra is carrying out a direct marketing campaign. Practices can take advantage of a special launch offer where they can purchase four vials and get a fifth free. The offer is available for a limited period only.
To find out more about Ketodale, call Dechra on 01743 441 632 or visiting www.dechra.com
Intervet/Schering-Plough Animal Health has announced that it is to sponsor the Equine Business Management Strategies (EBMS) program, a targeted business education program developed for equine veterinary surgeons and practice professionals.
According the company, this 5-day course has proven very successful in the United States. It had its European kick-off in Amsterdam on August 22, 2010, where a group of almost forty equine practitioners from North America and Europe gathered to discuss and learn how to apply business principles in their day-to-day work. The program was chaired by Dr. Joop Loomans, an equine veterinary surgeon responsible for equine business management education at the Department of Equine Sciences of the Veterinary Faculty of Utrecht University (The Netherlands).
Course participants worked with international specialists on strategic planning, benchmarking, branding and change management to create strategic plans to implement at their practices, and to share their knowledge, experience and ideas.
Intervet/Schering Plough says the launch of Equine Business Management Strategies program exceeded expectations of participants, sponsor and organizers. The chance to look at the day-to-day practice from a different angle and to learn about things like benchmarking exercises, revenue analysis and branding was highly appreciated. Participant Jeremy Mantell from Liphook Equine Hospital in the UK said: "The EBMS has given me a clearer understanding of what I need to change and develop in my practice."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering-Plough Animal Health said: "We believe that running an equine practice is not based solely on technical and scientific skills but also on effective practice management. That is why our company has decided to support this initiative. Intervet/Schering-Plough Animal Health also continues its custom of providing not only innovating products, but also new, value-added services to strengthen its bond with veterinarians."
Merial has launched Equioxx, a new pain management product which the company says is the first COX-2 specific NSAID for horses
Traditional NSAIDs act by blocking the action of both COX-1 and COX-2 enzymes at the same time. Although COX-2 produces prostaglandins associated with both inflammation and pain, COX-1 has a pivotal role in maintaining normal physiological function, so inhibiting this enzyme may have an increased risk of side effects e.g. gastric ulceration. Merial says Equioxx is the only NSAID that is highly COX-2 selective (up to 643 times more selective for COX-2 than COX-1), acting to reduce pain and inflammation but without affecting the COX-1 enzyme at therapeutic levels.
Equioxx contains the active ingredient firocoxib, and Merial says it is proven to be effective at reducing chronic lameness in horses. Appearing in blood plasma within 30 minutes of oral dosing, its pharmacokinetic profile allows once daily dosing. Field studies have confirmed that firocoxib is highly effective at controlling pain and improving function in horses with chronic osteoarthritis.
Equioxx is available as either a low dose injectable solution or a palatable oral paste.
For more information contact Merial Customer Services on 0870 6000 123
Every UK-based veterinary surgeon that registers as a member of www.vetsurgeon.org by 1st November 2010 will be entered into a draw to win an Apple iPad 32GB Wi-Fi worth £500.
All existing veterinary surgeon members will also be entered into the draw automatically, so there's no need to re-register. Still, you might like to spread the word about the draw amongst colleagues.
Full terms and conditions are available by clicking here.
CEVA Animal Health has produced Understanding sacroiliac disease, a leaflet to help horse owners understand the cause, diagnosis and management of sacroiliac disease.
CEVA says sacroiliac disease can be a particular challenge because although it can occur in isolation it often occurs in addition to other sources of hindlimb lameness. Acute sacroiliac injury is usually a result of trauma, such as a fall, which may cause pelvic rotation or fracture, resulting in hindlimb lameness and sensitivity to palpation of the tubera sacrale soon after injury. With chronic sacroiliac disease there is usually no history of trauma, rather a prolonged history of poor performance.
Understanding sacroiliac disease explains the anatomy of the sacroiliac joint, the clinical signs of the disease, how it is diagnosed, the treatment options and the general prognosis. The leaflet is available to equine vet practices as a useful information source for clients. You can order free copies from your CEVA sales representative.
Equine infectious anaemia (EIA) has been detected in a horse in Northumberland following importation from the Netherlands, Defra confirmed today.
The premises is currently under restriction and the infected horse will be humanely destroyed in line with existing regulations. The other horses on the premises are currently subject to epidemiological investigation.
The horse arrived in a group of six horses originating in the Netherlands and all have been tested for EIA as part of routine post-import testing. The other five horses in the group have all tested negative.
Chief Veterinary Officer Nigel Gibbens said: "This again shows the success of our post import testing regime. These were apparently healthy horses carrying a notifiable disease that we are keen to keep out of Great Britain. After considering the risk I have decided to take appropriate action and humanely destroy this horse."
Meanwhile, equine welfare charity World Horse Welfare is sending out an urgent plea to all horse owners across the UK and mainland Europe to work together in order to stop the increasing threat from this and a number of other diseases.
According to the charity, this case comes only eight months after the discovery of two horses suffering from the disease, which is notifiable, in Wiltshire. Those horses had been transported across Europe from Romania before being imported into the UK. Since the end of August alone, there have been new outbreaks reported in Northern France (directly linked to horses imported from Romania), the Dordogne area, and Germany.
World Horse Welfare Chief Executive Roly Owers said: "While World Horse Welfare welcomes the news that Defra has acted so promptly in dealing with this case, today's news is extremely concerning and demonstrates the changing environment we're living in. This is a real warning to us that we're sailing far too close to the wind. The concerning question is where these horses came from given that Holland to date has not reported a case of EIA.
"With more and more horses moving across Europe, including the significant trade in low value animals, not just slaughter animals, we're facing an increasing threat from the spread of disease. EIA is endemic in both Romania and Italy; Romania being one of the largest exporters and Italy being the largest importer of horses for slaughter in Europe. In spite of the legal requirement for health certification before exporting horses from Romania, which were tightened in June 2010, there continues to be cases of EIA across Europe.
"World Horse Welfare advises owners to undertake rigorous checks when buying a horse from abroad and is discouraging anyone from importing Romanian horses. Owners should also ensure that any horse they buy or that comes on to their yard has a passport, is checked for a microchip and that isolation and biosecurity measures are strictly followed for any new entry onto the yard. If this disease spreads across the UK it could have catastrophic effects on our horse population. Whether it's a child's pony or Cheltenham Gold Cup winner, disease does not discriminate."
Horiba Medical has announced it is the official exclusive UK distributor of the fully automated Vet abc Plus+ veterinary haematology analyser from scil animal care company GmbH, Germany.
According to the company, the compact Vet abc Plus+ provides a complete blood count (CBC), including 4-part white blood cell (WBC) differential, from only 10 µl of EDTA whole blood, in only 60 seconds.
The Vet abc Plus+ provides pre-installed settings to analyse samples from dogs, cats, horses, rabbits, mice, rats, cattle, pigs and sheep. For dogs, cats and horses, the Vet abc Plus+ provides a 4-part WBC differential blood count, including a differentiation of the leucocytes to identify lymphocytes, monocytes, granulocytes and eosinophils. Results are available in 60 seconds on screen or can be automatically printed out and transferred to the practice information system or clinical notes. For ease-of-use, the Vet abc Plus+ also incorporates a self-contained reagent and waste system which provides a clean operation whilst being easy to replenish.
Borne from an existing manufacturing partnership, scil and HORIBA Medical already have over 6000 veterinary haematology analysers placed globally. Horiba says the new UK distribution agreement enables UK veterinary professionals to not only procure the Vet abc Plus+ analyser, but also receive expert service and support directly from the manufacturer HORIBA Medical and its team of UK specialists.
For more information, visit: www.horiba.com/uk/medical
Pfizer Animal Health is reminding horse owners of the importance of treating encysted small redworm larvae this autumn.
According to the company, these hidden, dormant parasites can account for up to 90% of the redworm burden in a horse (1). Furthermore, encysted small redworm larvae won't show up in a faecal egg count (FEC). Even if a horse has shown a negative or low count it could still be harbouring several million harmful larvae, hidden within the gut wall (2)
Encysted small redworm are a potential time bomb, with the ability to survive inside a horse for up to two years. They usually 'wake-up' in the late winter or early spring, developing and emerging from the gut wall all at the same time. Such a sudden mass emergence can cause a disease syndrome known as 'larval cyathostominosis', causing diarrhoea and colic with up to a 50% mortality rate (2). Treating encysted small redworm successfully in the late autumn or early winter is vitally important in order to prevent this serious risk.
Pfizer says that Moxidectin, the key ingredient of EQUEST, is recognised as the only single dose treatment for encysted small redworm. It has been shown to kill the larvae in-situ, without resulting in severe inflammation of the gut wall that other multi-dose treatments may cause (3). In addition, Moxidectin is licensed for persistent activity against small redworm over two weeks, killing larvae ingested as the horse grazes for up to two weeks after treatment.
Ben Gaskell, Pfizer's veterinary advisor said: "A responsible and sustainable worming programme involves good pasture management, regular diagnostic tests and targeted worming, carefully planned using specialist advice. However, it is also vital to remember the danger of encysted small redworm. Even if a horse's FEC is clear, there could still be a significant encysted small redworm burden that must be treated properly every year in late autumn / early winter."
1) Bairden K. et al (2001) Veterinary Record 148, 138-141 2) Dowdall S.M.J. et al (2002) Veterinary Parasitology 106, 225‑242 3) Steinbach T. et al (2006) Veterinary Parasitology 139, 115‑131
BEVA President, Madeleine Campbell will be announcing plans for a veterinary-led European Transport Forum at BEVA Congress this year (8-11 September 2010), to discuss how the welfare of horses during transport can be improved through the better enforcement of legislation.
Dr Campbell is also the British Veterinary Association representative on the Federation of Veterinarians of Europe (FVE) working party for transport. The Forum, which will be held in Brussels on 29 November 2010, has been jointly organised by the FVE and BEVA and is sponsored by World Horse Welfare (WHW). It is hoped that it will be attended by over 150 participants, including representatives of EU Member States, CVOs, Members of the European Commission and European Parliament, scientific experts, national veterinary organisations, animal transport associations and animal welfare associations.
The Forum will review the enforcement of the existing European regulations that currently govern the transport of horses for slaughter and for other purposes. Areas for practical improvement will be identified with the key focus on the enforcement of current legislation and the role of vets in ensuring that the welfare of horses in transit is protected. The conference will endeavour to define the critical control points, effective control systems and good practices. It will also look into trade flows, animal health risks, horse identification and the effects of closing horse slaughterhouses.
Dr Campbell said: "It is all very well to campaign for new regulations but at present even the existing regulations are not being enforced adequately. The crux of the matter is enforcement and there are none better placed to help with this than vets. If we can all work collectively we should have the strength to make a real impact. This is what the Forum is about."
Dr Campbell will be speaking about the European Transport Forum at the Congress press conference on 10 September between 9am and 10am.
BEVA Congress runs from 8-11 September 2010 at the International Convention Centre, Birmingham. For further information and to register visit http://www.beva.org.uk/
Vetoquinol is introducing Equistro Kerabol Biotin, a complementary feeding stuff for horses which the company says can help maintain healthy hoof and hair growth when used daily.
Equistro Kerabol Biotin will replace Biometh Z and will be automatically supplied in its place when wholesaler stocks of Biometh Z are exhausted.
Equistro Kerabol Biotin is a complex of D-biotin, methionine and Ipaligo zinc in combination with organic selenium and Ipaligo manganese.
Available as a powder in a 3kg bucket which will last 200 days, Vetoquinol says Equistro Kerabol Biotin offers a cost-effective method of ensuring good quality hoof horn.
For more information about any Equistro product, please call 0800 169197 or speak to your local equine territory manager.
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x
Pfizer Animal Health has launched a dedicated Equine Business Unit to provide a higher level of service and a comprehensive range of products to equine vets across the UK.
Created following the merger with Fort Dodge, the Pfizer Equine Business Unit is headed by Ben Lacey MA Vet MB MRCVS, who has previously held both technical and sales roles at Pfizer. Ben and his team have a brief to offer a breadth of product, support and flexibility not previously available to equine vets.
The product range offered by the Pfizer Equine Business Unit includes the Equest range of parasiticides; the Duvaxyn vaccines for Equine Herpes Virus, West Nile Virus and Rotavirus and products such as Equimidine and Torbugesic. Also offered are existing Pfizer brands such as the Equip vaccine range, the antibiotic Excenel Sterile Powder, the NSAID Rimadyl for Horses and Depo-MedroneV.
Five experienced account managers with a strong track record in the equine sector have been appointed by Pfizer to build relationships with equine vet practices on a regional basis. They are:
South East England Mark BakerWest Midlands, Cheshire, Wales Laurie MayEast Anglia, East Midlands Penny McCannSouth West, South Wales Anna CunninghamThe North, Scotland Alexandra Cox
Ben Lacey said: "Building our new team and combining the highly regarded products offered previously by both Fort Dodge and Pfizer has proved a stimulating process. We've also worked closely with many of our existing practice customers to look at how we can develop the service we provide to them.
"We're now able to offer a product range which I believe is unrivalled in the market and a highly committed team of equine professionals, who share a vision and passion for equine health. We're looking forward to building our business with both existing and new customers in the months ahead."
Dechra Veterinary Products has launched free online Fluid Therapy Calculators to help veterinary staff calculate their patients' fluid requirements.
There are two versions available, small animal and equine. Both are available as an online tool or as a download to your desktop (note that to get hold of the desktop version, you need to try out the online calculator first).
For small animals, there are three options available. The M1/M2/M3 Plan calculates simple multiplications of the maintenance rate, while the Comprehensive Plan calculates fluid required to provide maintenance requirements, correct dehydration or replace ongoing losses. The third option, the Simple Rate Calculator, is a tool for calculating resuscitation fluid rates and can also be used for large animals. The Equine Plan calculates fluid requirements and infusion rates for both adult horses and foals.
Dechra says it has launched the calculators as the next component of its Vetivex Fluid support package. Along with the Fluids Knowledge Programme, this initiative aims to help veterinary staff across the UK to deliver effective fluid therapy.
Larry King, Product Manager at Dechra, said: "The calculators are a quick and easy reference tool for today's busy vet. You simply fill in the body weight and animal type, key in a few details and you have an instant but very accurate fluid rate calculated for you. It saves time and effort and ensures the animal is given the correct amount of fluid. The more effective the fluid therapy regime the faster the animal recovers."
The free Fluid Therapy Calculator is just one of a number of tools Dechra uses to support its Vetivex range of fluids. There is a range of downloadable reference documents, charts and guides available on the website http://www.fluidtherapy.co.uk/ including the Fluid Knowledge Programme and a full CPD Programme focused on effective fluid therapy.
Janssen Animal Health has launched Domosedan Gel, an oromucosal gel for the sedation of horses.
Janssen says Domosedan Gel, which contains 7.6 mg/ml (40mcg/kg) detomidine, induces sedation and analgesia with the efficacy and recovery comparable to Domosedan injection. Domosedan Gel is administered under the horse's tongue, so it is rapidly absorbed.
The company also says Domesedan Gel can replace physical restraint and improve safety during treatments, diagnostics and transport, and that the gel is ideal for horses that are nervous or needle-shy and when owners need more control during clipping, shoeing, dental treatments and boxing.
Nicki Glen, marketing manager at Janssen Animal Health said: "Domosedan Gel is proven to be both effective and easy-to-administer with 98% of horses accepting the gel and owners finding it easy and convenient to use.
"The gel starts to be absorbed immediately and demonstrates a reliable sedatory effect and high safety margin, making it an ideal solution for sedation and restraint when performing non invasive procedures on horses."
For further information, please contact your Janssen Animal Health territory manager.